Intravitreal injection of anti-VEGF agents has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy (PDR) [19, 20, 33, 34] and neovascular glaucoma (NVG) [24–32, 35] and for improving the vascular permeability in macular edema [11–18]. This evidence concerns the gene VEGFA and neovascular glaucoma.